Skip to main content

Allergies

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UCB Pharma
UCB PharmaBelgium - Brussels
1 program
Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an AntihistamineN/A1 trial
Active Trials
NCT00453583Completed4,581Est. Jan 2008
Sandoz
SandozAustria - Kundl
1 program
Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mgPHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaEvaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Clinical Trials (1)

Total enrollment: 4,581 patients across 1 trials

NCT00453583UCB PharmaEvaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Start: Mar 2007Est. completion: Jan 20084,581 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.